Published in Pharmacol Res on January 01, 1995
Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A (1999) 2.14
Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis. EMBO J (2000) 1.79
Conceptual foundations of the UCSD Statin Study: a randomized controlled trial assessing the impact of statins on cognition, behavior, and biochemistry. Arch Intern Med (2004) 1.50
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia (2002) 1.11
YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol (2000) 1.10
Enterococcus faecalis acetoacetyl-coenzyme A thiolase/3-hydroxy-3-methylglutaryl-coenzyme A reductase, a dual-function protein of isopentenyl diphosphate biosynthesis. J Bacteriol (2002) 1.09
Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci U S A (2004) 1.06
Bioerodible devices for intermittent release of simvastatin acid. Int J Pharm (2007) 1.04
Mutual amplification of apoptosis by statin-induced mitochondrial stress and doxorubicin toxicity in human rhabdomyosarcoma cells. Br J Pharmacol (2004) 1.02
Lovastatin alters cytoskeleton organization and inhibits experimental metastasis of mammary carcinoma cells. Clin Exp Metastasis (2002) 1.00
Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoA reductase. J Lipid Res (2011) 0.99
Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab (2014) 0.97
Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia. Blood (2012) 0.94
Mevalonate Pathway Blockade, Mitochondrial Dysfunction and Autophagy: A Possible Link. Int J Mol Sci (2015) 0.94
Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res (2014) 0.93
Amelioration of cisplatin-induced nephrotoxicity by statins. Indian J Pharmacol (2013) 0.88
Statins inhibit lymphocyte homing to peripheral lymph nodes. Immunology (2006) 0.88
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PLoS One (2012) 0.87
Does simvastatin stimulate bone formation in vivo? BMC Musculoskelet Disord (2003) 0.86
Simvastatin protects against cholestasis-induced liver injury. Br J Pharmacol (2008) 0.85
Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors. PLoS One (2010) 0.84
Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol (2003) 0.84
A novel statin-mediated "prenylation block-and-release" assay provides insight into the membrane targeting mechanisms of small GTPases. Biochem Biophys Res Commun (2010) 0.84
A statin-based inhibitor of lymphocyte function antigen-1 protects against ischemia/reperfusion-induced leukocyte adhesion in the colon. Br J Pharmacol (2003) 0.84
Rho-GTPase and Atherosclerosis: Pleiotropic Effects of Statins. J Am Heart Assoc (2015) 0.83
Manumycin inhibits ras signal transduction pathway and induces apoptosis in COLO320-DM human colon tumour cells. Br J Cancer (2000) 0.83
Effect of simvastatin on castration-resistant prostate cancer cells. Lipids Health Dis (2014) 0.82
Lovastatin lowers the risk of breast cancer: a population-based study using logistic regression with a random effects model. Springerplus (2016) 0.82
Hypercholesterolemia promotes an osteoporotic phenotype. Am J Pathol (2012) 0.82
FRET based quantification and screening technology platform for the interactions of leukocyte function-associated antigen-1 (LFA-1) with intercellular adhesion molecule-1 (ICAM-1). PLoS One (2014) 0.80
Statins and selective inhibition of Rho kinase protect small conductance calcium-activated potassium channel function (K(Ca)2.3) in cerebral arteries. PLoS One (2012) 0.80
Combination of 13-Cis retinoic acid and lovastatin: marked antitumor potential in vivo in a pheochromocytoma allograft model in female athymic nude mice. Endocrinology (2014) 0.79
Bioactivity guided fractionation and hypolipidemic property of a novel HMG-CoA reductase inhibitor from Ficus virens Ait. Lipids Health Dis (2015) 0.79
Purification, crystallization and preliminary X-ray analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase of Streptococcus pneumoniae. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.79
Bark Extracts of Ceylon Cinnamon Possess Antilipidemic Activities and Bind Bile Acids In Vitro. Evid Based Complement Alternat Med (2017) 0.78
Optimized zein nanospheres for improved oral bioavailability of atorvastatin. Int J Nanomedicine (2015) 0.77
In vitro screening for β-hydroxy-β-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk. Biomed Res Int (2014) 0.77
Amyloid-β peptide on sialyl-Lewis(X)-selectin-mediated membrane tether mechanics at the cerebral endothelial cell surface. PLoS One (2013) 0.76
Characterization and application of a newly synthesized 2-deoxyribose-5-phosphate aldolase. J Ind Microbiol Biotechnol (2012) 0.76
Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol (1996) 0.76
Virtual pathway explorer (viPEr) and pathway enrichment analysis tool (PEANuT): creating and analyzing focus networks to identify cross-talk between molecules and pathways. BMC Genomics (2015) 0.75
Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials. Saudi Med J (2016) 0.75
In vitro Anti-Tumor Effects of Statins on Head and Neck Squamous Cell Carcinoma: A Systematic Review. PLoS One (2015) 0.75
A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med (2016) 0.75
Moderate alcohol use and health: a consensus document. Nutr Metab Cardiovasc Dis (2013) 2.77
Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purif (2006) 1.40
Low density lipoprotein oxidation, antioxidants, and atherosclerosis. Curr Opin Cardiol (2000) 1.33
Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol (2007) 1.27
Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin (2007) 1.19
Barriers to cardiovascular disease risk scoring and primary prevention in Europe. QJM (2010) 1.06
Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis (1993) 1.06
In vivo assimilation of low density lipoproteins by a fibrosarcoma tumour line in mice. Cancer Lett (1984) 1.04
Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition. Nutr Metab Cardiovasc Dis (2011) 1.03
Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med (2007) 1.03
High density lipoprotein cholesterol levels are an independent predictor of the progression of chronic kidney disease. J Intern Med (2013) 1.00
MicroRNA 143-145 deficiency impairs vascular function. Int J Immunopathol Pharmacol (2012) 0.98
Assimilation of LDL by experimental tumours in mice. Biochim Biophys Acta (1989) 0.97
Activation of lipoprotein lipase by synthetic fragments of apolipoprotein C-II. Ann N Y Acad Sci (1980) 0.97
Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis (1986) 0.96
Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med (2005) 0.94
Liver X receptor and retinoic X receptor agonists modulate the expression of genes involved in lipid metabolism in human endothelial cells. Int J Mol Med (2005) 0.94
Acute effect of high-fat meal on endothelial function in moderately dyslipidemic subjects. Arterioscler Thromb Vasc Biol (2004) 0.93
Familial defective apo B-100, characterization of an Italian family. Eur J Clin Invest (1991) 0.92
Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100. Atherosclerosis (1992) 0.92
Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis (2009) 0.92
Bile lipid composition and haemostatic variables in a case of high density lipoprotein deficiency (Tangier disease). Eur J Clin Invest (1984) 0.91
Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Cardiovasc Res (2003) 0.90
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol (1995) 0.89
Plasma lipids, lipoproteins and apoproteins in a case of apo C-II deficiency. Clin Chim Acta (1983) 0.88
Different patterns characterize Omega 6 and Omega 3 long chain polyunsaturated fatty acid levels in blood from Italian infants, children, adults and elderly. Prostaglandins Leukot Essent Fatty Acids (2013) 0.88
HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol (2004) 0.87
Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a pro-inflammatory response in the endothelium: Molecular mechanisms and gene expression studies. J Mol Cell Cardiol (2006) 0.87
Subfractionation of human very low density lipoproteins by heparin-Sepharose affinity chromatography. J Lipid Res (1983) 0.87
Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population. J Intern Med (2014) 0.86
Oxidized-LDL induce the expression of heat shock protein 70 in human endothelial cells. Biochem Biophys Res Commun (1994) 0.86
Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes. Arterioscler Thromb Vasc Biol (1995) 0.86
Unique epitope of apolipoprotein A-I expressed in pre-beta-1 high-density lipoprotein and its role in the catalyzed efflux of cellular cholesterol. Biochemistry (1994) 0.86
Direct effects of statins on the vascular wall. J Cardiovasc Pharmacol (1998) 0.86
Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2. Pharmacol Res (1990) 0.86
Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol (1996) 0.86
Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Atherosclerosis (2009) 0.86
Oxidized LDL increase free cholesterol and fail to stimulate cholesterol esterification in murine macrophages. Biochem Biophys Res Commun (1990) 0.85
Simvastatin modulates the heat shock response and cytotoxicity mediated by oxidized LDL in cultured human endothelial smooth muscle cells. Biochem Biophys Res Commun (1997) 0.85
Oxidized LDL induce hsp70 expression in human smooth muscle cells. FEBS Lett (1995) 0.84
Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology (1997) 0.84
Defective catabolism of oxidized LDL by J774 murine macrophages. J Lipid Res (1992) 0.83
Effects of calcium antagonists on lipids and atherosclerosis. Am J Cardiol (1989) 0.83
Comparative in vitro study of the pro-apolipoprotein A-I to apolipoprotein A-I converting activity between normal and Tangier plasma. J Clin Invest (1984) 0.83
Suppression of 3-hydroxy-3-methylglutaryl-CoA reductase by low density lipoproteins produced in vitro by lipoprotein lipase action on nonsuppressive very low density lipoproteins. J Biol Chem (1979) 0.83
Stress proteins and atherosclerosis. Atherosclerosis (1996) 0.83
Lipid lowering activity of drugs affecting cholesterol absorption. Nutr Metab Cardiovasc Dis (2004) 0.82
Lipolysis of ApoC-II deficient very low density lipoproteins: enhancement of lipoprotein lipase action by synthetic fragments of apoC-II. Biochem Biophys Res Commun (1979) 0.82
Abnormal suppression of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by hypertriglyceridemic very low density lipoprotein subclasses. Lipids (1980) 0.82
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis (1999) 0.81
Human endothelial cells exposed to oxidized LDL express hsp70 only when proliferating. Arterioscler Thromb Vasc Biol (1996) 0.81
Overexpression of inducible heat shock protein 70 in Cos-1 cells fails to protect from cytotoxicity of oxidized ldls. Arterioscler Thromb Vasc Biol (2001) 0.81
Effect of lercanidipine and its (R)-enantiomer on atherosclerotic lesions induced in hypercholesterolemic rabbits. Br J Pharmacol (1998) 0.80
Effect of the apolipoprotein C-II/C-III1 ratio on the capacity of purified milk lipoprotein lipase to hydrolyse triglycerides in monolayer vesicles. Atherosclerosis (1996) 0.80
Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res (1996) 0.80
Quantification of apoC-II and apoC-III of human very low density lipoproteins by analytical isoelectric focusing. J Lipid Res (1978) 0.79
Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis (1998) 0.79
Antioxidants and coronary artery disease. Curr Opin Lipidol (1998) 0.79
Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein-receptor interaction. J Lipid Res (1992) 0.79
Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: possible role of oxidised LDL. Nutr Metab Cardiovasc Dis (2002) 0.79
Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations. Eur Heart J (1991) 0.79
Apolipoprotein C-II deficiency: detection of immunoreactive apolipoprotein C-II in the intestinal mucosa of two patients. J Lipid Res (1988) 0.79
Apolipoprotein C-II and lipoprotein lipase activity. Ric Clin Lab (1982) 0.78
Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia. J Clin Invest (1986) 0.78
Radial-immunodiffusion assay of human apolipoprotein A-I with use of two monoclonal antibodies combined. Clin Chem (1986) 0.78
Effect of lacidipine on the carotid intimal hyperplasia induced by cuff injury. J Cardiovasc Pharmacol (1994) 0.77
Prostaglandin synthetase activity in vascular tissue of male and female rats. Prostaglandins (1980) 0.77
Identification of domains in apoA-I susceptible to proteolysis by mast cell chymase. Implications for HDL function. J Lipid Res (2000) 0.77
Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation. Pharmacol Res (1993) 0.77
A dot-blot assay for the low density lipoprotein receptor. J Lipid Res (1987) 0.77
Effect of lacidipine on fatty and proliferative lesions induced in hypercholesterolaemic rabbits. Br J Pharmacol (1996) 0.77
Immunochemical characterization of six monoclonal antibodies to human apolipoprotein A-I: epitope mapping and expression. J Lipid Res (1990) 0.77
Binding-defective low-density lipoprotein in family with hypercholesterolaemia. Lancet (1989) 0.77
Localization of apolipoprotein A-I epitopes involved in the activation of lecithin:cholesterol acyltransferase. J Lipid Res (1996) 0.77
Native LDL and oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-kappaB, CRE dependent pathway and affect PGE2 synthesis. Int J Mol Med (2004) 0.76
Guidelines on CVD prevention: confusing or complementary? Atherosclerosis (2012) 0.76
Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes. Pharmacol Res (1991) 0.76
Evidence for the presence of 7-hydroperoxycholest-5-en-3 beta-ol in oxidized human LDL. Chem Phys Lipids (1992) 0.76
Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by intramuscular injection of plasmid DNA. Gene Ther (2000) 0.76
Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. Transplantation (1999) 0.76
Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab (2012) 0.75
Hypobetalipoproteinemia associated with apo B-48.4, a truncated protein only 14 amino acids longer than apo B-48. Atherosclerosis (1998) 0.75
Effect of partial ileal bypass on plasma clearance and binding of lipoproteins to liver membranes in the rabbit. Atherosclerosis (1983) 0.75
A new case of familial LCAT deficiency. Acta Med Scand (1983) 0.75
The distribution of apo C-II and apo C-III in very low density lipoproteins of normal and type IV subjects. Atherosclerosis (1980) 0.75
Experimental studies on the hypolipidemic activity of chloridarol. Pharmacol Res Commun (1983) 0.75
Formation of high density lipoprotein-like particles from chylomicrons. Ric Clin Lab (1982) 0.75
In vitro catabolism of human very low density lipoproteins: fate of apoproteins B and C. Artery (1981) 0.75
Pharmacological studies on tiadenol in type IV patients. Evidence for a mechanism of action different from other lipid-lowering drugs. Atherosclerosis (1982) 0.75
Glycosaminoglycans and lipoprotein metabolism: an overview. Pharmacol Res Commun (1979) 0.75
Reduced apoprotein B and increased lipoprotein turnover in cholesterol-fed rabbits after partial ileal bypass. Surgery (1981) 0.75
The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press Suppl (1998) 0.75